Adra1D is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Adrenergic receptor involved in stress response and cognition
The ADRA1D gene (Alpha-1D Adrenergic Receptor) is located on chromosome 20p13 and encodes a protein involved in G protein-coupled receptor signaling. This gene has been implicated in several neurodegenerative diseases and neuropsychiatric disorders.
| Attribute | Value |
|---|---|
| Symbol | ADRA1D |
| Full Name | Alpha-1D Adrenergic Receptor |
| Chromosomal Location | 20p13 |
| NCBI Gene ID | 5626 |
| OMIM | 104190 |
| Ensembl ID | ENSG00000149532 |
| UniProt ID | P25100 |
The ADRA1D gene encodes the alpha-1D adrenergic receptor, the least well-characterized alpha-1 subtype. Like other alpha-1 receptors, it is Gq-coupled and activates PLC signaling. In the brain, alpha-1D receptors are expressed in the hippocampus, cortex, and thalamus, where they modulate stress responses, attention, and memory consolidation. The receptor plays roles in synaptic plasticity and may influence neurodegeneration through effects on cerebral blood flow and neuroinflammation. Genetic variants in ADRA1D have been associated with PTSD risk and may affect fear memory consolidation.
The ADRA1D gene has been linked to the following diseases:
High expression in hippocampus (CA1, CA3, dentate gyrus), cerebral cortex (particularly frontal and parietal lobes), thalamus (including the thalamic reticular nucleus), hypothalamus, and locus coeruleus. Also expressed in cerebral arteries and pia mater.
Alpha-1D-selective antagonists (silodosin, tamsulosin) are used for benign prostatic hyperplasia. Tamsulosin has been associated with intraoperative floppy iris syndrome. In neurodegeneration, alpha-1D blockade may reduce neuroinflammation and improve cerebral blood flow. The receptor may be a target for post-traumatic stress disorder treatment.
ADRA1D signals through Gq/11 proteins, leading to activation of phospholipase C (PLC) and subsequent generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). This results in calcium release from intracellular stores and activation of protein kinase C (PKC).
Alpha-1D adrenergic receptor antagonists (tamsulosin, silodosin) are used to treat benign prostatic hyperplasia but can cause orthostatic hypotension. Selective ADRA1D antagonists are being developed for urological applications.
Selectivity for ADRA1D over ADRA1A and ADRA1B remains challenging due to high sequence homology. Newer compounds aim to achieve better uroselectivity while minimizing cardiovascular side effects.
The study of Adra1D has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
ADRA1D variants are associated with:
ADRA1D modulators:
ADRA1D knockout mice show: